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SUMMARY AIDS-associated Kaposi’s sarcoma (KS) isthe
mostcommon AIDS-relatedmalignancyin sub-Saharan
Africa, withagenerally unfavourable prognosis.We report
onsix-monthand12-monthcohort treatmentoutcomesof
humanimmunodeficiency virus (HIV)-positive KS patients
and HIV-positivenon-KS patientstreated withantiretro-
viraltherapy(ART)inpublic sector facilitiesinMalawi.Data
were collected from standardizedantiretroviral (ARV)
patientmastercards and ARV patientregisters. Between
Julyand September 2005,7905 patients started ART-488
(6%) witha diagnosisofKS and 7417 witha non-KS diag-
nosis. BetweenJanuaryand March 2005, 4580 patients
startedART-326 (7%) withadiagnosisof KS and 4254 with
a non-KS diagnosis. At six-months and12-months, signifi-
cantly fewer KS patients were alive and significantly more
had diedor defaultedcompared tonon-KS patients. HIV-
positive KS patients on ART in Malawihaveworse out-
comesthan other patients on ART . Methods designed to
improve these outcomes mustbe found.
Introduction
Endemic Kaposi’s sarcoma (KS), a multifocal neoplasm
involving predominately skin and mucous membranes, has
been reported sporadically from sub-Saharan African
countries for many years. However, with the advent of
human immunodeﬁciency virus (HIV) infection, epidemic
or AIDS-associated KS has become by far the most
common form of the tumour and also the most common
AIDS-related malignancy observed in clinical practice.
1
Treatment options in industrialized countries include sys-
temic or combination chemotherapy (commonly used drugs
being vincristine, vinblastine, bleomycin, doxorubicin and
dacarbazine), interferon alfa and radiation therapy.
1 Even
though none of these, in the absence of highly active antire-
troviral therapy (ART), provides a cure for AIDS-associated
KS,
2 they do allow signiﬁcant palliation. Unfortunately, in
most poorly resourced African countries these treatment
modalities are not available and treatment for the most part
has been conﬁned to pain relief and to the treatment of sec-
ondary infections.
The advent of ART has changed the natural history of KS
in HIV-positive individuals. Response rates of KS to ART of
up to 90% have been observed in some studies, with com-
plete remission in patients with good immunological
responses, in patients with no systemic symptoms and those
where lesions are conﬁned to the skin.
3,4 Disease-free survi-
val of HIV-positive patients started on ART due to KS has
also signiﬁcantly improved.
5 Until two or three years ago,
ART was only available in industrialized countries.
However, with the World Health Organization’s (WHO) ‘3
by 5’ initiative, many resource-poor countries started
scaling up ART for their HIV-infected communities. By
December 2005, over 800,000 patients had been commenced
on ART in Africa.
6 While the availability of ART has
renewed the enthusiasm for treating KS, to our knowledge
there is a scarcity of published information about outcomes
for KS patients in Africa who have been treated with ART
under routine programme conditions.
Every three months the HIV unit of the Ministry of Health,
Malawi, and its partners conduct supervisory and monitoring
visits to all sites in the country that are delivering ART in the
publicsector.Dataarecollectedonthenumbersandcharacter-
istics of patients starting ART and their outcomes. We used
these structured visits to obtain additional information on out-
comes of KS patients who had been started on ART, and com-
pared their outcomes with those for non-KS patients on ART.
Methods
Background
Scaling up and delivering ART in Malawi The process
and nature of ART scale-up in Malawi has already been
described,
7,8 and only the main elements will be described
below. A standardized, structured approach is used which
includes
† a focus on one generic, ﬁxed-dose combination treatment
with stavudine, lamivudine and nevirapine to be deliv-
ered free of charge to HIV-positive eligible patients;
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reporting of cases and outcomes and
† quarterly supervision and evaluation of all ART sites.
Two alternative ﬁrst-line regimens (for any serious side
effects of ART drugs) and one second-line regimen (for
ART drug failure) have been placed in central hospitals
and two district hospitals. A referral system has also been
set up to enable patients in need to access the appropriate
therapy.
Facilities in the public health sector have been selected in a
phased approach for antiretroviral (ARV) scale-up and now,
after training the staff and formally accrediting the sites,
they have started to deliver ART. By March 2006, 66 sites
were delivering ART using the national standardized
systems.
When a patient is found to be HIV-positive, referral is
made to the ARV clinic for clinical staging. If the patient
is found to be eligible for ART (assessed as being WHO
Clinical Stage 3 or 4 or with a CD4-lymphocyte count
,200/mm
3), he/she is asked to attend, accompanied by a
guardian, for a group counselling/brieﬁng session conducted
by one of the ARV clinic staff in order to be given infor-
mation about ART. The patient is then asked to return a
few days to a week later for individual counselling and for
the start of ART. Patients are then followed up, ﬁrst at two
weeks and thereafter at four-week intervals, with assessments
and drugs distributed from the ARV clinic.
Management of patients with KS Patients with KS
will be HIV tested and counselled; those who are
HIV-positive will be eligible for ART because they are in
WHO clinical stage 4 category.
9 For patients with bulky
tumours or visceral involvement, the usual clinical practice
in Malawi is to treat them with vincristine, administered as
an intravenous dose of 2 mg once a week, for two to three
weeks before commencing ART. They must then complete
a total of six weeks of vincristine.
Monitoring and evaluation for ART During the
monthly ART monitoring visits, vital data is recorded
using standardized monitoring tools such as the ARV
patient master cards and ARV register.
7 Standardized treat-
ment outcomes are recorded every month on the master
cards and updated in the ARV register. Every three months
a quarterly cohort analysis is performed on the most recent
three-month cohort of patients started on ART and the cumu-
lative cohort of all patients started on therapy. Facilities
record case ﬁnding characteristics and treatment outcomes
at a set point in time; these are checked and collated by the
HIV unit and its partners during the quarterly supervisory
visits.
10
Data collection
By the end of March 2006, there were 66 sites in the public
sector delivering ART to patients. They were all visited
between April and June 2006. Data for quarterly and cumu-
lative cohort analyses were collected into a structured pro-
forma, and then entered into an Excel spread sheet for
collation. Sixty sites had started patients on ART between
1 July and 30 September 2005, and their treatment outcomes
were censored on 31 March 2006 to provide a so-called six-
month cohort survival analysis: in effect this means an analy-
sis of patient outcomes six to nine months after starting ART.
Between 1 January and 31 March 2005 there were 35 sites
that had started patients on ART. Their treatment outcomes
were also censored on 31 March 2006 to provide a so-called
12-month cohort survival analysis: this, in effect, means an
analysis of patient outcomes 12–15 months after starting
ART. In addition, during these same two quarterly periods
patients registered as having KS were identiﬁed from the
ARV patient master cards, and their outcomes were censored
on 31 March 2006 to provide a six-month and 12-month sur-
vival analysis for KS patients.
Analysis
Six-month and 12-month survival outcomes were performed
for patients with KS. The numbers of KS patients and their
outcome data were subtracted from all patients started on
ART during the same time periods, and a calculation was
made for survival outcomes for non-KS patients.
Differences in treatment outcomes between groups were
compared using the x
2-test. Relative risks (RR) and 95%
conﬁdence intervals (CI) were obtained, with differences at
the level of 0.05 being regarded as signiﬁcant.
Results
Between 1 July and 30 September 2005, 7905 patients started
ART-488 (6%) with a diagnosis of KS and 7417 with another
non-KS diagnosis. The six-month cohort outcomes of KS and
non-KS patients censored on 31 March 2006 are shown in
Table 1. At six months, signiﬁcantly fewer KS patients
Table 1 Six-month and 12-month outcomes in quarterly
cohorts of Kaposi’s sarcoma (KS) patients and non-KS
patients started on antiretroviral treatment (ART) in Malawi
in 2005, with outcomes censored on 31 March 2006
Treatment
outcome
parameter
KS
patients
Non-KS
patients RR (95% CI)
a P-value
Six-month treatment outcomes
Number started
on ART
488 7417
Number (%)
alive
b
277 (57) 5426 (73) 0.78 (0.72–0.84) ,0.001
Number (%)
dead
c
111 (23) 861 (12) 1.96 (1.64–2.33) ,0.001
Number (%)
defaulted
d
65 (13) 589 (8) 1.68 (1.32–2.13) ,0.001
Number (%)
stopped
e
5 (1) 54 (1) 1.41 (0.57–3.50) NS
Number (%)
transferred
f
30 (6) 487 (6) 0.94 (0.66–1.34) NS
12-month treatment outcomes
Number started
on ART
326 4254
Number (%)
alive
b
172 (53) 2801 (66) 0.80 (0.72–0.89) ,0.001
Number (%)
dead
c
71 (22) 509 (12) 1.82 (1.46–2.27) ,0.001
Number (%)
defaulted
d
48 (15) 462 (11) 1.36 (1.03–1.79) ,0.05
Number (%)
stopped
e
6 (2) 46 (1) 1.70 (0.73–3.96) NS
Number (%)
transferred
f
29 (8) 436 (10) 0.87 (0.61–1.24) NS
aRR between KS patients and non-KS patients
bAlive and on ARTat the facility where the patient registered for therapy
cDied for any reason
dNo attendance at the antiretroviral clinic for three months or longer for
no known reason
eStopped treatment for any reason
fPermanently transferred out to another treatment facility
CI, conﬁdence interval; NS, not signiﬁcant; RR, relative risks
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the non-KS patients.
Between 1 January and 31 March 2005, 4580 patients
started ART-326 (7%) with a diagnosis of KS and 4254
with another non-KS diagnosis. The 12-month cohort out-
comes of KS and non-KS patients censored on 31 March
2006 are also shown in Table 1. At 12 months, signiﬁcantly
fewer KS patients were alive and signiﬁcantly more had died
or defaulted compared to non-KS patients.
Discussion
In both quarters, between 5–10% of patients starting ART
were placed on treatment because they had KS. The pro-
portion of KS patients alive at six-months and 12-months
was signiﬁcantly lower compared to other non-KS patients:
this was due to higher death rates and default rates. Default
means loss to follow-up, and unpublished data suggest that
a large percentage of defaulters are, in fact, patients who
have died. Despite these inferior results, over half the patients
with KS and on ART were still alive one year after commen-
cing treatment.
This was an operational study conducted within the routine
system and therefore has all the limitations of this type of
research. Data were not collected on the demographic charac-
teristics of patients, the extent of disease (which has been
shown to inﬂuence prognosis),
3 or HIV – or drug-related
morbidity or causes of death. We also have no information
about how many KS patients received their vincristine.
There was a general shortage of the drug in country during
the latter half of 2005, with 35% of ART facilities having
completely run out of stock of vincristine between July and
September 2005 (source: HIV Unit, Ministry of Health,
Malawi). However, the strengths of the study were that it
was countrywide, the routine systems for monitoring patients
using master cards and registers are robust and regularly
checked by supervising teams, and we believe that the
results are reliable and representative. The use of six-month
and 12-month quarterly cohort analysis is now well estab-
lished and enables survival analyses to be carried out as
part of the routine system. For busy ART facilities and super-
vising teams with scarce human resources, individual patient
survival outcomes are too time-consuming to carry out.
Cohort survival analysis, however, is quick and reliable pro-
vided the registers are regularly updated.
There are many aspects that require further assessment. In
particular, treatment outcomes in the routine setting need to
be analysed in relation to (1) the staging of AIDS-KS, par-
ticularly bulk of the disease, pulmonary involvement and sys-
temic illness and (2) the usefulness of prior and continuation
treatment with cytotoxic chemotherapy with either vincris-
tine or bleomycin (the latter given by intramuscular injection
which is easier to administer). However, in resource-poor
countries there are always going to be difﬁculties in procur-
ing and accessing cytotoxic drugs. It is therefore necessary
to identify KS patients earlier in the disease when ART on
its own is likely to provide signiﬁcant beneﬁts in terms of
reducing the bulk of disease and improving long-term
survival.
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SUMMARY We reviewed the scientific literature on
Burkitt’s lymphoma (BL) in Africain order to provideinfor-
mationonthe current status ofclinical care and the exist-
ingresearch challenges. BL epidemiologyled tothe
discoveryof the Epstein Barr virus, animportant cause of
several viralillnesses andmalignancies.Theincidence of BL
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